In JAMS arbitration, CRA was retained by the Claimant regarding a dispute involving the breach of fiduciary duty by former employees of a clinical stage therapeutic company. CRA estimated the Claimant’s cash flows using contemporaneous Claimant’s financial data, colorectal cancer incidence rates and treatment prices, relevant clinical trial and generic market entry studies, and potentially comparable companies financials. Such information, along with qualitative information, was considered to estimate the Claimant’s risk-adjusted net present value. Claimant presented our valuation methodology and work product in its mediation, which CRA attended.
Recent Trends in Rule 702 Decisions
In this CRA Insights, we update the Rule 702 Decision trends in last year’s Insights with 2022 data. We also provide three examples of specific challenges in...